Evidence map›Paper›PMID 31564044›Full record

ArticleInternational journal of clinical pharmacy2019

Experience with a colorectal cancer campaign in Swiss pharmacies.

Martine Ruggli, Daniela Stebler, Markus Gasteiger, Maria Trottmann, Philip Hochuli, Harry Telser, Fabian Vaucher

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Early cancer diagnosis and community pharmacies: a systematic review.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026
    Pooled it
  2. The Co-Design of an Evidence-Based Health Education Strategy to Improve Bowel Cancer Awareness and Screening in a Remote Tasmanian Community: Lessons Learned.Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Martine RugglipharmaSuisse, The Swiss Association of Pharmacists, Stationsstrasse 12, 3097, Bern-Liebefeld, Switzerland. martine.ruggli@bluewin.ch.ORCID http://orcid.org/0000-0003-4055-0050
Daniela SteblerpharmaSuisse, The Swiss Association of Pharmacists, Stationsstrasse 12, 3097, Bern-Liebefeld, Switzerland.
Markus GasteigerpharmaSuisse, The Swiss Association of Pharmacists, Stationsstrasse 12, 3097, Bern-Liebefeld, Switzerland.
Maria TrottmannSwica Healthcare Insurance, Zurich, Switzerland.
Philip HochuliPolynomics, Olten, Switzerland.
Harry TelserPolynomics, Olten, Switzerland.
Fabian VaucherpharmaSuisse, The Swiss Association of Pharmacists, Stationsstrasse 12, 3097, Bern-Liebefeld, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Colorectal cancer is the third most common cancer worldwide. Screening with several methods can accurately detect early-stage cancer and polyps and reduce colorectal cancer mortality in adults aged 50 to 75 years. Objective Test the feasibility, interest and potential impact of a colorectal cancer screening in Swiss community pharmacies. Setting 771 community pharmacies of Switzerland participated in a 6-week campaign. Method The pharmacists evaluated the risk factors through a questionnaire among individuals aged between 50 to 75 years old who did not have had a colonoscopy over the previous 10 years. Pharmacists delivered a Faecal Immunochemical Test (FIT) to those without risk. Patients with identified risk factors or with a positive result were referred to a physician. Patients with a negative result were given lifestyle advice and invited for a new screening in two years. Main outcome measure The impact was measured through the number of persons screened, of tests delivered and of referrals to a physician performed. Results Within 6 weeks, 23,024 persons were screened in pharmacies. In total, 760 patients (3%) had risk factors and were directly referred to physicians. The remaining 22,264 received a FIT, and 97% of these individuals performed and sent the FIT to the laboratory. Of the 21,701 tests analysed, 93% were negative. All individuals with positive results (7%) were referred to a physician. Conclusion Having the opportunity to take colorectal cancer prevention measures with a low threshold, like in a community pharmacy encourages the population to perform the screening.

Indexed as

AgedColorectal NeoplasmsCommunity Pharmacy ServicesDiagnostic Tests, RoutineEarly Detection of CancerFecesFemaleHumansLife StyleMaleMass ScreeningMiddle AgedPharmacistsReferral and ConsultationRisk FactorsSurveys and QuestionnairesColorectal cancerCommunity pharmacyFaecal immunochemical testing (FIT)ScreeningSwitzerland

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.